# EDGAR Filing Document

**Accession Number:** 0001907108
**File Stem:** 0001415889-25-015606
**Filing Date:** 2025-6
**Character Count:** 82741
**Document Hash:** c34447fa5ae6137913024a403377c841
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001415889-25-015606.hdr.sgml**: 20250604

**ACCESSION NUMBER**: 0001415889-25-015606

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250604

**DATE AS OF CHANGE**: 20250604

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexeo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001907108
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854012572
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94231
- **FILM NUMBER:** 251023840

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 547-9879

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Frazier Life Sciences Public Fund, L.P.
- **CENTRAL INDEX KEY:** 0001863769

**ORGANIZATION NAME:**
- **EIN:** 862999645
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 PAGE MILL ROAD
- **STREET 2:** BUILDING 4, SUITE B
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** 650-325-5156

**MAIL ADDRESS:**
- **STREET 1:** 1001 PAGE MILL ROAD
- **STREET 2:** BUILDING 4, SUITE B
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

## Exhibit 99.1

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT**

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Lexeo Therapeutics, Inc.

Date: June 4, 2025

**FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.**

By: FHMLSP, L.P., its General Partner

By: FHMLSP, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLSP, L.P.**

By: FHMLSP, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLSP, L.L.C.**

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.**

By: FHMLSP Overage, L.P., its General Partner

By: FHMLSP Overage, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLSP OVERAGE, L.P.**

By FHMLSP Overage, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLSP OVERAGE, L.L.C.**

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

------

Date: June 4, 2025

**FRAZIER LIFE SCIENCES X, L.P.**

By: FHMLS X, L.P., its General Partner

By: FHMLS X, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLS X, L.P.**

By: FHMLS X, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLS X, L.L.C.**

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FRAZIER LIFE SCIENCES XI, L.P.**

By: FHMLS XI, L.P., its General Partner

By: FHMLS XI, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLS XI, L.P.**

By: FHMLS XI, L.L.C., its General Partner

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FHMLS XI, L.L.C.**

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, Chief Financial Officer

Date: June 4, 2025

**FRAZIER LIFE SCIENCES XII, L.P.**

By: FHMLS XII, L.P., its General Partner

By: FHMLS XII, L.L.C., its General Partner

By: <u>/s/ Gordon Empey</u>

Gordon Empey, General Counsel

Date: June 4, 2025

**FHMLS XII, L.P.**

By: FHMLS XII, L.L.C., its General Partner

By: <u>/s/ Gordon Empey</u>

Gordon Empey, General Counsel

Date: June 4, 2025

**FHMLS XII, L.L.C.**

By: <u>/s/ Gordon Empey</u>

Gordon Empey, General Counsel

Date: June 4, 2025

By: <u>\*</u>

James N. Topper

Date: June 4, 2025

By: <u>\*</u>

Patrick J. Heron

Date: June 4, 2025

By: <u>\*\*</u>

Albert Cha

Date: June 4, 2025

By: <u>\*\*</u>

James Brush

Date: June 4, 2025

By: <u>\*\*\*</u>

Daniel Estes

Date: June 4, 2025

By: <u>/s/ Steve R. Bailey</u>

Steve R. Bailey, as Attorney-in-Fact

\* This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017.

\*\*This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

\*\*\*This Joint Filing Agreement was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Lexeo Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, $0.0001 par value per share

**CUSIP Number:** 52886X107

**Date of Event Which Requires Filing of this Statement:** 05/28/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Frazier Life Sciences Public Fund, L.P. | Names of Reporting Persons<br>Frazier Life Sciences Public Fund, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3730419.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3730419.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3730419.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3730419.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.8% | Percent of Class Represented by Amount in Row (9)<br>6.8% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLSP, L.P. | Names of Reporting Persons<br>FHMLSP, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3730419.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3730419.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3730419.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3730419.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.8% | Percent of Class Represented by Amount in Row (9)<br>6.8% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLSP, L.L.C. | Names of Reporting Persons<br>FHMLSP, L.L.C. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>3730419.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>3730419.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3730419.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>3730419.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.8% | Percent of Class Represented by Amount in Row (9)<br>6.8% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Frazier Life Sciences Public Overage Fund, L.P. | Names of Reporting Persons<br>Frazier Life Sciences Public Overage Fund, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>818607.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>818607.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>818607.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>818607.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.5% | Percent of Class Represented by Amount in Row (9)<br>1.5% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLSP Overage, L.P. | Names of Reporting Persons<br>FHMLSP Overage, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>818607.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>818607.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>818607.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>818607.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.5% | Percent of Class Represented by Amount in Row (9)<br>1.5% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLSP Overage, L.L.C. | Names of Reporting Persons<br>FHMLSP Overage, L.L.C. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>818607.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>818607.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>818607.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>818607.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.5% | Percent of Class Represented by Amount in Row (9)<br>1.5% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P. and (ii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Frazier Life Sciences X, L.P. | Names of Reporting Persons<br>Frazier Life Sciences X, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>114541.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>114541.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>114541.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>114541.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.2% | Percent of Class Represented by Amount in Row (9)<br>0.2% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLS X, L.P. | Names of Reporting Persons<br>FHMLS X, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>114541.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>114541.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>114541.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>114541.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.2% | Percent of Class Represented by Amount in Row (9)<br>0.2% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLS X, L.L.C. | Names of Reporting Persons<br>FHMLS X, L.L.C. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>114541.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>114541.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>114541.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>114541.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.2% | Percent of Class Represented by Amount in Row (9)<br>0.2% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P. and (ii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Frazier Life Sciences XI, L.P. | Names of Reporting Persons<br>Frazier Life Sciences XI, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>304989.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>304989.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>304989.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>304989.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.6% | Percent of Class Represented by Amount in Row (9)<br>0.6% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLS XI, L.P. | Names of Reporting Persons<br>FHMLS XI, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>304989.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>304989.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>304989.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>304989.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.6% | Percent of Class Represented by Amount in Row (9)<br>0.6% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLS XI, L.L.C. | Names of Reporting Persons<br>FHMLS XI, L.L.C. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>304989.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>304989.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>304989.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>304989.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.6% | Percent of Class Represented by Amount in Row (9)<br>0.6% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P. and (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 16, 2025. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Frazier Life Sciences XII, L.P. | Names of Reporting Persons<br>Frazier Life Sciences XII, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>532256.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>532256.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>532256.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>532256.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.0% | Percent of Class Represented by Amount in Row (9)<br>1.0% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLS XII, L.P. | Names of Reporting Persons<br>FHMLS XII, L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>532256.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>532256.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>532256.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>532256.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.0% | Percent of Class Represented by Amount in Row (9)<br>1.0% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>FHMLS XII, L.L.C. | Names of Reporting Persons<br>FHMLS XII, L.L.C. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>532256.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>532256.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>532256.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>532256.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.0% | Percent of Class Represented by Amount in Row (9)<br>1.0% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (ii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025. FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025 and (iii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>James N. Topper | Names of Reporting Persons<br>James N. Topper |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>5500812.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>5500812.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5500812.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5500812.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.9% | Percent of Class Represented by Amount in Row (9)<br>9.9% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vii) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (ix) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.  FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vi) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (vii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Patrick J. Heron | Names of Reporting Persons<br>Patrick J. Heron |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>5500812.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>5500812.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5500812.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>5500812.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>9.9% | Percent of Class Represented by Amount in Row (9)<br>9.9% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 87,424 shares of Common Stock held directly by Frazier Life Sciences X, L.P., (vi) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vii) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (viii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (ix) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (x) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.  FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.  FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.  FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (v) 27,117 shares of Common Stock issuable to Frazier Life Sciences X, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (vi) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (vii) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Albert Cha | Names of Reporting Persons<br>Albert Cha |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>4549026.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>4549026.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4549026.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4549026.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>8.3% | Percent of Class Represented by Amount in Row (9)<br>8.3% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>James Brush | Names of Reporting Persons<br>James Brush |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>4549026.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>4549026.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4549026.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>4549026.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>8.3% | Percent of Class Represented by Amount in Row (9)<br>8.3% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 3,073,467 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P., (ii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 624,804 shares of Common Stock held directly by Frazier Life Sciences Public Overage Fund, L.P., and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.  FHMLSP Overage, L.P. is the general partner of Frazier Life Sciences Public Overage Fund, L.P. and FHMLSP Overage, L.L.C. is the general partner of FHMLSP Overage, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Overage Fund, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 656,952 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 193,803 shares of Common Stock issuable to Frazier Life Sciences Public Overage Fund, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

| 1. | Names of Reporting Persons<br>Daniel Estes | Names of Reporting Persons<br>Daniel Estes |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>837245.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>837245.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>837245.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>837245.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>1.5% | Percent of Class Represented by Amount in Row (9)<br>1.5% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** The shares listed in rows 6, 8 and 9 consist of (i) 232,784 shares of Common Stock held directly by Frazier Life Sciences XI, L.P., (ii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, (iii) 406,246 shares of Common Stock held directly by Frazier Life Sciences XII, L.P. and (iv) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P. Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XI, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XI, L.P.  FHMLS XII, L.P. is the general partner of Frazier Life Sciences XII, L.P. and FHMLS XII, L.L.C. is the general partner of FHMLS XII, L.P.  Patrick J. Heron, James N. Topper and Daniel Estes are the members of FHMLS XII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences XII, L.P.

The percentage listed in row 11 is calculated based the sum of (i) 33,196,997 shares of the Issuer's Common Stock outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q/A filed with the SEC on May 15, 2025, (ii) 20,790,120 shares of Common Stock that were sold by the Issuer in connection with its public offering as set forth as described in the Issuer's Current Report on Form 8-K filed with the SEC on May 27, 2025, (iii) 72,205 shares of Common Stock issuable to Frazier Life Sciences XI, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025, and (iv) 126,010 shares of Common Stock issuable to Frazier Life Sciences XII, L.P. pursuant to warrants and pre-funded warrants exercisable within 60 days of May 28, 2025.

---

**Item 1(a). Name of Issuer:**
Lexeo Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010.

**Item 2(a). Name of Person Filing:**
The entities and persons filing this statement (collectively, the "Reporting Persons") are:

Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P. FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
Frazier Life Sciences XII, L.P. ("FLS XII")
FHMLS XII, L.P.
FHMLS XII, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")

**Item 2(b). Address of Principal Business Office:**
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304

**Item 2(c). Citizenship:**
Entities:		FLSPF 				        -	Delaware, U.S.A.
			FHMLSP, L.P.			        -	Delaware, U.S.A.
			FHMLSP, L.L.C.		        -	Delaware, U.S.A.
			FLSPOF			                -	Delaware, U.S.A.
			FHMLSP Overage, L.P.		-	Delaware, U.S.A.
			FHMLSP Overage, L.L.C.	-	Delaware, U.S.A.
			FLS X				        -	Delaware, U.S.A.
			FHMLS X, L.P.			-	Delaware, U.S.A.
			FHMLS X, L.L.C.		        -	Delaware, U.S.A.
			FLS XI				        -	Delaware, U.S.A.
			FHMLS XI, L.P.		        -	Delaware, U.S.A.
			FHMLS XI, L.L.C.		        -	Delaware, U.S.A.
			FLS XII				        -	Delaware, U.S.A.
			FHMLS XII, L.P.		        -	Delaware, U.S.A.
			FHMLS XII, L.L.C.		        -	Delaware, U.S.A.

Individuals:	Topper				        -	United States Citizen
			Heron				        -	United States Citizen
			Cha				                -	United States Citizen
			Brush				        -	United States Citizen
			Estes				        -	United States Citizen

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**Item 2(e). CUSIP Number:**
52886X107

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

**(b) Percent of class:**

The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.  Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of Topper's and Heron's cover pages have been rounded down from 9.99% to 9.9%.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.

**(ii) Shared power to vote or to direct the vote:**

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

**(iii) Sole power to dispose or to direct the disposition of:**

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.

**(iv) Shared power to dispose or to direct the disposition of:**

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Frazier Life Sciences Public Fund, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.

**FHMLSP, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.

**FHMLSP, L.L.C.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLSP, L.L.C.

**Frazier Life Sciences Public Overage Fund, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.

**FHMLSP Overage, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.

**FHMLSP Overage, L.L.C.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.

**Frazier Life Sciences X, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.

**FHMLS X, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.

**FHMLS X, L.L.C.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLS X, L.L.C.

**Frazier Life Sciences XI, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.

**FHMLS XI, L.P.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.

**FHMLS XI, L.L.C.**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, CFO of FHMLS XI, L.L.C.

**Frazier Life Sciences XII, L.P.**

**Date:** 06/04/2025

**By:** /s/ Gordon Empey

**Name & Title:** By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.

**FHMLS XII, L.P.**

**Date:** 06/04/2025

**By:** /s/ Gordon Empey

**Name & Title:** By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.

**FHMLS XII, L.L.C.**

**Date:** 06/04/2025

**By:** /s/ Gordon Empey

**Name & Title:** By Gordon Empey, General Counsel of FHMLS XII, L.L.C.

**James N. Topper**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017

**Patrick J. Heron**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017

**Albert Cha**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

**James Brush**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021

**Daniel Estes**

**Date:** 06/04/2025

**By:** /s/ Steve R. Bailey

**Name & Title:** By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022